

Blood and Transplant

Board Meeting in Public

Tuesday, 06 June 2023

Title of Report	Board Effectiveness Review Action Plan	Agenda No.	4.1.2
Nature of Report (tick one)	<input checked="" type="checkbox"/> Official	<input type="checkbox"/> Official Sensitive	
Author(s)	Brenda Thomas, Interim Company Secretary		
Lead Executive	Helen Gillan, Director of Quality		
Non-Executive Director Sponsor (if applicable)	Peter Wyman, NHSBT Chair		
Presented for (tick all that applies)	<input checked="" type="checkbox"/> Approval <input checked="" type="checkbox"/> Assurance	<input type="checkbox"/> Information <input type="checkbox"/> Update	
Purpose of the report and key issues			
<p>An internal Board effectiveness review was undertaken in December 2022. The findings of the review with proposed recommendations were discussed at the Board seminar in March 2023.</p> <p>The Board reviewed the recommendations, and an action plan has been developed to take forward the agreed recommendations. Progress of the action plan will be monitored by the Executive Team and a progress report provided to the Board.</p>			
Previously Considered by			
The Executive Team on 17 May 2023.			
Recommendation	The Board is asked to approve the Board Effectiveness Review Action Plan.		
Risk(s) identified (Link to Board Assurance Framework Risks)			
Linked to Regulatory Compliance risk (BAF-09).			
Strategic Objective(s) this paper relates to: [Click on all that applies]			
<input checked="" type="checkbox"/> Collaborate with partners <input checked="" type="checkbox"/> Invest in people and culture <input checked="" type="checkbox"/> Drive innovation <input checked="" type="checkbox"/> Modernise our operations <input checked="" type="checkbox"/> Grow and diversify our donor base			
Appendices:	Appendix 1: Board Effectiveness Review Action Plan.		